NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel cancer therapeutics, today announced that it has enrolled the first patient in a disease-directed Phase II clinical trial of IMC-1121B to treat advanced malignant melanoma. IMC-1121B is ImClone’s fully human IgG1 vascular endothelial growth factor receptor-2 (VEGFR-2) monoclonal antibody.
